Overview

A Study of OSI-7904L as Treatment in Patients With Head and Neck Cancer Who Have Failed First-Line Therapy

Status:
Completed

Trial end date:
2005-08-01

Target enrollment:

Participant gender:

Summary

Multi-center, Phase II study to evaluate the efficacy and safety of OSI-7904Lin head and neck cancer in patients who have failed first-line therapy

Phase:

Phase 2

Details

Lead Sponsor:

OSI Pharmaceuticals